PPTA Presents at ESID 2012

PPTA presents at the 15th Biennial Meeting of the European Society of Immunodeficiencies (ESID 2012) held in collaboration with the International Patient Organisation of Patients with Immunodeficiency (IPOPI) and the International Nurses Group for Immune Deficiency (INGID).

October 3-6
Florence, Italy

Presentations:

"A Decision Analysis Model for Estimating Latent Therapeutic Demand for Immunoglobulin Therapy in Primary Immune Deficiencies" - Albert Farrugia, Vice President, PPTA Global Access

"The Production of Safe Plasma Derivatives from Vein to Vein" - Jan M. Bult, PPTA President and CEO

Created on June 25 2012.

Media and Information

PPTA News

Monkeypox Virus and Plasma Protein Therapies +

PPTA considers that the current MPXV outbreak is not a concern for the safety margins of plasma protein therapies manufactured by PPTA member companies. This assessment is also shared by other concerned parties (AABB, WHO).

Since May 2022, Monkeypox virus (MPXV) infections have been reported in non-endemic countries across Europe and North America (WHO, CDC, ECDC). People who use plasma protein therapies are understandably concerned about whether their therapies remain safe, with respect to MPXV. To address this issue, PPTA has summarized currently available facts.
Read More
Announcing PPTA’s New Global Chair +

It is with great pleasure that the Plasma Protein Therapeutics Association (PPTA) announces the election of Giles Platford from Takeda to the Chair of the PPTA Global Board.
Read More
Public Review until August 31: Proposed Confirmation of IQPP Standard for Recording Donor Adverse Events +
The following proposed actions are hereby opened for public review:
- Confirmation (continued implementation) of Version 2.0 of the IQPP Standard for Recording Donor Adverse Events
Resulting from a scheduled review by the PPTA IQPP Standards Committee and discussion by the PPTA Global Plasma Board of Directors, it was agreed that this document should be “confirmed.” In other words, it was agreed that the document should continue to be implemented as part of the IQPP Standards Program, without change. Members of the public are invited to comment on this proposed action. The text of the standards themselves is not being considered for revision at this time.
Read More
PPTA's 2021 Annual Report Now Available +

On March 16, PPTA published its 2021 Annual Report, providing an overview of the Association’s activities throughout the year. This year’s digital report offers readers an engaging and interactive experience as they read about PPTA’s work on behalf of its global membership and in support of patients who rely on plasma-derived therapies. We invite you to read the report here.
Read More

› ‹

The Source, the international magazine of the plasma protein therapeutics industry, is published three times a year.

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives.
Find a Donation Center.

The need for plasma and plasma donors is more urgent than ever before. Visit givingplasma.org to learn more and to find a donation center near you.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

PPTA Presents at ESID 2012

Media and Information

Advocacy